Mr. Peter B. Hutt is Independent Director at DBV Technologies SA, Independent Director at XOMA Corp., Independent Director at ISTA Pharmaceuticals, Inc., Independent Director at Momenta Pharmaceuticals, Inc., a Professor at Harvard University, Senior Advisor at Kearny Venture Partners, Senior Counsel at Covington & Burling LLP, an Advisor at InCube Venture Partners LLC, an Advisor at New Leaf Venture Partners LLC, a Member at National Academy of Sciences, Independent Director at Q Holdings, Inc., a Director & Strategic Advisor at Longwood Fund Management LLC, and a Member at Institute of Medicine.
He is on the Board of Directors at DBV Technologies SA, Concert Pharmaceuticals, Inc., XOMA Corp., ISTA Pharmaceuticals, Inc., Momenta Pharmaceuticals, Inc., Pervasis Therapeutics, Inc., Q Therapeutics, Inc., Seventh Sense Biosystems, Inc., Endotis Pharma SA, Living Proof, Inc., BIND Biosciences, Inc., Q Holdings, Inc., Blend Therapeutics, Inc., Longwood Fund Management LLC, Life Line Screening of America Ltd., Nanomedical Systems, Inc., and Selecta Biosciences, Inc.
Mr. Hutt was previously employed as Chief Counsel by US Food & Drug Administration, Legal Counsel by American College of Toxicology, Legal Counsel by Society for Risk Analysis, Partner by Covington & Burling LLP, and Senior Regulatory Counsel by Edison Pharmaceuticals, Inc.
He also served on the board at Celera Corp., Introgen Therapeutics, Inc., Favrille, Inc., CV Therapeutics, Inc., Celera Group, IDEC Pharmaceuticals Corp., National Institutes of Health, Phase Forward, Inc., and Quick-Med Technologies, Inc.
Mr. Hutt received his undergraduate degree from Yale University, a graduate degree from New York University, and a graduate degree from Harvard Law School.